PEDIATRICS Vol. 66 No. 5 November 1980, pp. 799-800
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Enhorning, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Enhorning, G.

Artificial Surfactant to Prevent and Treat Neonatal Respiratory Distress Syndrome

Goran Enhorning MD1

1 Department of Obstetrics and Gynaecology, University of Toronto and The Toronto Western Hospital, Toronto

Twenty years ago we were first presented with evidence that infants dying from hyaline membrane disease suffer from a pulmonary surfactant deficiency.1 This observation has been substantiated with numerous reports from several countries. It offers a logical explanation to the physiology and pathology characterizing the condition, and has clearly influenced preventive and therapeutic measures. The obstetrician tries to avoid delivery until surfactant synthesis has become adequate through a naturally occurring process of maturation, or through one stimulated with glucocorticoids, and the pediatrician counteracts the tendency for atelectasis to develop by applying an airway pressure which is continuously distending.

Delivery quite often occurs so early in gestation that surfactant synthesis is still inadequate and there has not been sufficient time to stimulate it.